Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer

Clinical Therapeutics

Volumn 27, Issue 10, 2005, Pages 1513-1534

  Smith, Janine ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Epidermal growth factor receptor inhibitor; Erlotinib; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ATAZANAVIR; BEVACIZUMAB; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CLARITHROMYCIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; HYPERICUM PERFORATUM EXTRACT; IRINOTECAN; KETOCONAZOLE; NAVELBINE; PACLITAXEL; PEMETREXED; PHENOBARBITAL; PHENYTOIN; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; UNINDEXED DRUG; VINBLASTINE;

ABDOMINAL PAIN; ABORTION; ACNE; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; CORNEA ULCER; COUGHING; DATA BASE; DERMATITIS; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRY SKIN; DYSPNEA; EMBASE; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MATERNAL DISEASE; MEDICAL LITERATURE; MEDLINE; METASTASIS; NAUSEA; PATHOGENESIS; PNEUMONIA; PREGNANCY; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; REVIEW; RISK FACTOR; SKIN TOXICITY; STOMATITIS; TIME SERIES ANALYSIS; VOMITING;

EID: 28444489982     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.10.014     Document Type: Article

References (99)

1. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997, by the American Society of Clinical Oncology J Clin Oncol 15 1997 2996 3018
2. Herbst R.S., and Bunn P.A. Jr Targeting the epidermal growth factor receptor in non-small cell lung cancer Clin Cancer Res 9 2003 5813 5824
3. Baselga J., and Hammond L.A. HER-targeted tyrosine-kinase inhibitors Oncology 63 Suppl 1 2002 6 16
4. Zielinski S.L. Tarceva wins approval from FDA J Natl Cancer Inst 96 2004 1811
5. Tarceva[package insert] 2005 OSI Pharmaceuticals, Inc Melville, NY
6. New Orleans, La. Abstract 7022 Shepherd F.A., Pereira J., and Ciuleanu T.E. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1 st or 2nd line chemotherapy. Study BR.21 Presented at: 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) June 5-8 2004
7. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T. National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2 2005 123 132
8. Ciardiello F., and Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor Clin Cancer Res 7 2001 2958 2970
9. Dai Q., Ling Y.H., and Lia M. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumorcell lines Clin Cancer Res 11 2005 1572 1578
10. Available at: American Cancer Society Cancer facts and figures Accessed February 28, 2005 2005
11. Jernal A., Murray T., and Ward E. Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
12. Available at: Centers for Disease Control and Prevention, and National Center for Health Statistics National vital statistics reports Accessed March 22 2005 Cancer-Lung Cancer Statistics
13. Available at: National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). Seer Stat database. Cancer StatFacts: Cancer of the Lung Accessed March 22 2005
14. Available at: National Cancer Institute Non-small cell lung cancer (PDQ): Treatment 2005 Accessed February 28 2005
15. Available at: National Comprehensive Cancer Network Clinical practice guidelines in oncology. Version 2.2005 Accessed February 28 2005
16. Schrump D., Altorki N., and Henschke C. Non-small cell lung cancer DeVita V.T. Jr Hellman S. Rosenberg S.A. Cancer: Principles & Practice of Oncology 7th ed. 2005 Lippincott Williams & Wilkins Philadelphia 753 777
17. Karp D.D., and Thurer R. Non-small cell lung cancer Furie B. Atkins M. Mayer R. Cassileth P. Clinical Hematology and Oncology: Presentation, Diagnosis and Treatment 2003 Churchill Livingstone Philadelphia 958 979
18. Edelman M.J., and Gandara D.R. Lung cancer Casciato D. Lowitz B.B. 5th ed. Manual of Clinical Oncology 2000 Lippincott Williams & Wilkins Philadelphia 157 171
19. Lung malignancies Ferrari M. PDxMD Hematology & Oncology 2003 PDxMD Philadelphia, Pa 462 502
20. Ihde D.C. Chemotherapy of lung cancer N Engl J Med 327 1992 1434 1441
21. Ihde D.C., and Minna J.D. Non-small cell lung cancer. Part I: Biology, diagnosis and staging Curr Probl Cancer 15 1991 61 104
22. Martini N., and Flehinger B.J. The role of surgery in N2 lung cancer Surg Clin North Am 67 1987 1037 1049
23. Mountain C.F. Prognostic implications of the International Staging System for Lung Cancer Semin Oncol 15 1988 236 245
24. Lilenbaum R.C. Treatment of patients with advanced lung cancer and poor performance status Clin Lung Cancer 6 Suppl 2 2004 S71 S74
25. Dowell J., Minna J.D., and Kirkpatrick P. Erlotinib hydrochloride Nat Rev Drug Discov 4 2005 13 14
26. Shepherd F.A., Dancey J., and Ramlau R. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treat ed with platinum-based chemotherapy.) J Clin Oncol 18 2000 2095 2103
27. [published correction appears in J Clin Oncol. 2004;22:209] Fossella F.V., DeVore R., Kerr R.N. TAX 320 Non-Small Cell Lung Cancer Study Group Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell-lung cancer previously treated with platinum-containing chemotherapy regimens J Clin Oncol 18 2000 2354 2362
28. Publication 48 World Health Organization Handbook for reporting results of cancer treatment 1979 WHO Geneva, Switzerland
29. Perez-Soler R. HER1/EGFR targeting: Refining the strategy Oncologist 9 2004 58 67
30. Mass R.D. The HER receptor family: A rich target for therapeutic development Int J Radiat Oncol Biol Phys 58 2004 932 940
31. Gatzemeier U. Targeting the HER1/ EGFR receptor to improve outcomes in non-small-cell lung can cer Oncology (Williston Park) 17 Suppl 12 2003 7 10
32. Harari P.M., and Huang S.M. Modulation of molecular targets to enhance radiation Clin Cancer Res 6 2000 323 325
33. Janmaat M.L., and Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors Oncologist 8 2003 576 586
34. Herbst R.S. Erlotinib (Tarceva): An update on the clinical trial program Semin Oncol 30 Suppl 7 2003 34 46
35. Thomas M. Epidermal growth factor receptor tyrosine kinase inhibitors: Application in non-small cell lung cancer Cancer Nurs 26 Suppl 6 2003 21S 25S
36. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, smallmolecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and futuredirections J Clin Oncol 23 2005 2556 2568
37. Bulgaru A.M., Mani S., Goel S., and Perez-Soler R. Erlotinib (Tarceva): A promising drug targeting epidermal growth factor receptor tyrosine kinase Exp Rev Anticancer Ther 3 2003 269 279
38. Grunwald V., and Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment J Natl Cancer Inst 95 2003 851 867
39. Grunwald V., and Hidalgo M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774) Adv Exp Med Biol 532 2003 235 246
40. Gibson A., and Lee D. XII European Cancer Conference, Copenhagen, Denmark: Activity of erlotinib (OSI 774, Tarceva) in bronchoalveolar carcinoma Clin Lung Cancer 5 2004 203
41. Belani C.P., and Ramalingam S. Lung cancer: Looking ahead in 2004 Clin Lung Cancer 5 2004 200
42. Tamura K., and Fukuoka M. Molecular target-based cancer therapy: Tyrosine kinase inhibitors Int J Clin Oncol 8 2003 207 211
43. Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small-cell lung cancer Clin Cancer Res 10 2004 4238s 4240s
44. Arteaga C.L. EGF receptor as a therapeutic target: Patient selection and mechanisms of resistance to receptortargeted drugs J Clin Oncol 21 Suppl 23 2003 289s 291s
45. Yano S., Kondo K., and Yamaguchi M. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition Anticancer Res 23 2003 3639 3650
46. Seymour L. Epidermal growth factor receptor inhibitors: An update on their development as cancer therapeutics Curr Opin lnvestig Drugs 4 2003 658 666
47. Khalil M.Y., Grandis J.R., and Shin D.M. Targeting epidermal growth factor receptor: Novel therapeutics in the management of cancer Expert Rev Anticancer Ther 3 2003 367 380
48. Baselga J., and Albanell J. Targeting epidermal growth factor receptor in lung cancer Curr Oncol Rep 4 2002 317 324
49. Ciardiello F., and Tortora G. Antiepidermal growth factor receptor drugs in cancer therapy Expert Opin lnvestig Drugs 11 2002 755 768
50. de Bono J.S., and Rowinsky E.K. The ErbB receptor family: A therapeutic target for cancer Trends Mol Med 8 Suppl 4 2002 S19 S26
51. Slichenmyer W.J., and Fry D.W. Anticancer therapy targeting the erbB family of receptor tyrosine kinases Semin Oncol 28 Suppl 16 2001 67 79
52. Jimeno A., and Hidalgo M. Blockade of epidermal growth factor receptor (EGFR) activity Crit Rev Oncol Hematol 53 3 2005 179 192
53. Krozely P. Epidermal growth factor receptor tyrosine kinase inhibitors: Evolving role in the treatment of solid tumors Clin J Oncol Nurs 8 2004 163 168
54. Stamos J., Sliwkowski M.X., and Eigenbrot C. Structure of the epidermal growth factor receptor kinase do main alone and in complex with a 4-anilinoquinazoline inhibitor J Biol Chem 277 2002 46265 46272
55. Normanno N., Bianco C., and De Luca A. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment Endocr Relat Cancer 10 2003 1 21
56. Tsao M.S., Sakurada A., and Cutz J.C. Erlotinib in lung cancer-molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
57. Perez-Soler R., Chachoua A., and Hammond L.A. Determinants of tumor response and survival with er lotinib in patients with non-smallcell lung cancer J Clin Oncol 22 2004 3238 3247
58. Dancey J.E. Predictive factors for epidermal growth factor receptor inhibitors-the bull's-eye hits the arrow Cancer Cell 5 2004 411 415
59. Parra H.S., Cavina R., and Latteri F. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (Iressa, ZD1839) in non-small-cell lung cancer Br J Cancer 91 2004 208 212
60. Meert A.P., Martin B., and Delmotte P. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis Eur Respir J 20 2002 975 981
61. Lynch T.J., Bell D.W., and Sordella R. Activating mutations in the epidermal growth factor receptor under-lying responsiveness of non-smallcell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
62. Paez J.G., Janne P.A., and Lee J.C. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
63. Pao W., Miller V., and Zakowski M. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc National Acad Sci U S A 101 2004 13306 13311
64. Kobayashi S., Boggon T.J., and Dayaram T. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
65. Shigematsu H., Lin L., and Takahashi T. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
66. Perea S., and Hidalgo M. Predictors ofsensitivity and resistance to epidermal growth factor receptor inhibitors Clin Lung Cancer 6 Suppl 1 2004 S30 S34
67. Available at: American Society of Clinical Oncology Role of EGFR mutations in clinical practice examined Accessed May 2005
68. Iressa [package insert] 2005 AstraZeneca Pharmaceuticals LP Wilmington, Del
69. Evans T.L. Highlights from the Tenth World Conference on Lung Cancer Oncologist 9 2004 232 238
70. Abstract 1166 Kris M., Natale R.B., and Herbst R.S. A phase II trial of ZD 1839 ("Iressa") in advanced non-small cell lung can cer (NSCLC) patients who had failed platinum and docetaxel-basedregimens (IDEAL-2) Proc Am Soc Clin Oncol 21 2002 292a
71. Results of ISEL study 2004 AstraZeneca Pharmaceuticals LP Wilmington, Del
72. Hidalgo M., Siu L.L., and Nemunaitis J. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267 3279
73. Moyer J.D., Barbacci E.G., and Iwata K.K. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 1997 4838 4848
74. Pollack V.A., Savage D.M., and Baker D.A. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice J Pharmacol Exp Ther 291 1999 739 748
75. Malik S.N., Siu L.L., and Rowinsky E.K. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients Clin Cancer Res 9 2003 2478 2486
76. Shin D.M., Donato N.J., and Perez-Soler R. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin Cancer Res 7 2001 1204 1213
77. Hidalgo M., Malik S., and Rowinsky E. Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients Proc Am Soc Med Oncol 20 2001 281
78. Hidalgo M., and Bloedow D. Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva) Semin Oncol 30 Suppl 7 2003 25 33
79. Available at: Clinical Pharmacology Online Clinical Pharmacology: Erlotinib Accessed March 31 2005
80. Available at: Micromedex Products Erlotinib Accessed March 31 2005
81. Kim T.E., and Murren J.R. Erlotinib OSI/Roche/Genentech Curr Opin Investig Drugs 3 2002 1385 1395
82. Birner A. Pharmacology of oral chemotherapy agents Clin J Oncol Nurs 7 Suppl 6 2003 11 19
83. Abstract 596 Rakhit A., Fettner S., and Riek S. Clinical pharmacokinetics of erlotinib in healthy subjects Proc Am Soc Clin Oncol 22 2003 149
84. Abstract 548 Abbas R., Fettner S., and Riek M. A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor,erlotinib, in healthy subjects Proc Am Soc Clin Oncol 22 2003 137
85. Adjei A.A., and Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy J Clin Oncol 23 2005 5386 5403
86. ASCO Abstract 7010 Gatzemeier U., Pluzanska A., and Szczesna A. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced nonsmall cell lung cancer(NSCLC) Proc Am Soc Clin Oncol 23 2004
87. ASCO Abstract 7011 Herbst R.S., Prager D., and Hermann R. TRIBUTE: A Phase III trial of erlotinib HCI (OSI-774) continued with carboplatinum and paclitaxel (CP) chemotherapy in advanced non-small cell lungcancer (NSCLC) Proc Am Soc Clin Oncol 23 2004
88. Herbst R.S., Prager D., and Hermann R. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
89. (Suppl) Miller V.A., Herbst R., and Prager L. Long survival of never smoking nonsmall cell lung cancer (NSCLC) pa tients treated with erlotinib HCI (OSI-774) and chemotherapy: Subgroup analysisof TRIBUTE J Clin Oncol 22 2004 14S
90. Sandler A.B., Blumenschein R., and Henderson T. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HERl/EGFR-TK inhibitor, for patients with recurrent nonsmall cell lung cancer J Clin Oncol 22 Suppl 14 2004 2000
91. Herbst R.S., Johnson D.H., and Mininberg E. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermalgrowth factor receptor tyrosine kinase inhibitor erlotinib for patients with non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
92. Avastin [package insert] 2004 Genentech, Inc South San Francisco, Calif
93. Available at National Cancer Institute Cancer progress report-2003 update. Costs of cancer care Accessed March 31 2005
94. Drug Topics Redbook 2005 2005 Thomson Healthcare Montvale, NJ
95. Adis International Ltd. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415 Drugs R D 4 2003 243 248
96. Leslie W.T., and Bonomi P.D. Novel treatments in non-small cell lung cancer Hematol Oncol Clin North Am 18 2004 245 267
97. Bonomi P. Erlotinib: A new therapeutic approach for non-small cell lung cancer Expert Opin Investig Drugs 12 2003 1395 1401
98. Kamb A. What's wrong with our cancer models? Nat Rev Drug Discov 4 2005 161 165
99. Betensky R.A., Louis D.N., and Cairncross J.G. Influence of unrecognized molecular heterogeneity on randomized clinical trials J Clin Oncol 20 2002 2495 2499